{"title":"约旦高脂血症患者LDL受体和CETP基因变异与阿托伐他汀反应之间无关联","authors":"Malek Zihlif, Suhad Otoum, Mohammad Al Shhab, Zaid Almadani, Monther Momani, Hussam Alhawari, Esraa Jibrini, Yazun Jarrar, Hamzeh Al-Ameer, Amer Imraish","doi":"10.1515/dmpt-2021-0177","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (<i>CETP</i>) and LDL receptor (<i>LDLR</i>) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR <i>AvaII</i>, <i>CETP TaqIb,</i> and <i>Rs1532624</i> on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.</p><p><strong>Methods: </strong>One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of <i>LDLR AvaII</i> and <i>CETP TaqIb</i> genetic variants. The genotyping of <i>CETP Rs1532624</i> variant was done by Sanger DNA-Sequencing.</p><p><strong>Results: </strong>LDLR <i>AvaII</i> and <i>CETP TaqIb</i> and <i>Rs1532624</i> variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.</p><p><strong>Conclusions: </strong>Results demonstrated a significant association between the <i>LDLR AvaII</i> and <i>CETP TaqIb,</i> and <i>Rs1532624</i> genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"No association between LDL receptor and <i>CETP</i> genetic variants and atorvastatin response in Jordanian hyperlipidemic patients.\",\"authors\":\"Malek Zihlif, Suhad Otoum, Mohammad Al Shhab, Zaid Almadani, Monther Momani, Hussam Alhawari, Esraa Jibrini, Yazun Jarrar, Hamzeh Al-Ameer, Amer Imraish\",\"doi\":\"10.1515/dmpt-2021-0177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (<i>CETP</i>) and LDL receptor (<i>LDLR</i>) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR <i>AvaII</i>, <i>CETP TaqIb,</i> and <i>Rs1532624</i> on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.</p><p><strong>Methods: </strong>One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of <i>LDLR AvaII</i> and <i>CETP TaqIb</i> genetic variants. The genotyping of <i>CETP Rs1532624</i> variant was done by Sanger DNA-Sequencing.</p><p><strong>Results: </strong>LDLR <i>AvaII</i> and <i>CETP TaqIb</i> and <i>Rs1532624</i> variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.</p><p><strong>Conclusions: </strong>Results demonstrated a significant association between the <i>LDLR AvaII</i> and <i>CETP TaqIb,</i> and <i>Rs1532624</i> genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.</p>\",\"PeriodicalId\":11332,\"journal\":{\"name\":\"Drug metabolism and personalized therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug metabolism and personalized therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/dmpt-2021-0177\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2021-0177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients.
Objectives: Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (CETP) and LDL receptor (LDLR) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR AvaII, CETP TaqIb, and Rs1532624 on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.
Methods: One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of LDLR AvaII and CETP TaqIb genetic variants. The genotyping of CETP Rs1532624 variant was done by Sanger DNA-Sequencing.
Results: LDLR AvaII and CETP TaqIb and Rs1532624 variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.
Conclusions: Results demonstrated a significant association between the LDLR AvaII and CETP TaqIb, and Rs1532624 genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.
期刊介绍：
Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
